Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential sales. “We know how to make and develop drugs ...

CEO Len Schleifer, M.D., Ph.D., was asked about disappointing sales of high-dose Eylea. “I’d be happier to talk about the pipeline,” Schleifer said. Earlier on Monday, Regeneron shared ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...